Global Glycobiology Market is projected to grow at a CAGR of 14.8% during the forecast period 2020-2027
A new research report published by Fior Markets with the title Glycobiology Market by Product (Kits, Enzymes, reagents, instruments), Application (Immunology, Drug Discovery and Development, Oncology, Diagnostics, others), region, global industry analysis, market size, share, growth, trends, and forecast 2020 to 2027.
The global Glycobiology market is expected to grow from USD 1.00 billion in 2019 to USD 2.82 billion by 2027, at a CARG of 14.8% during the forecast period 2020-2027.
North America has the largest market share because of presence of key biopharmaceutical companies and pharmaceutical. Accessibility to advanced products and presence of well-established healthcare infrastructure are driving the regional market of glycobiology. Asia-Pacific is predicted to be the second fasted growing region due to untapped market opportunities.
NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418269/request-sample
The key players of this market are Shizmadzu Corporation, Merck KGaA, Bruker Corporation, Plexera Bioscience LLC, Agilent Technologies Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., New England Biolabs Inc., and PoZyme Inc.
The Thermo Fisher Scientific Inc., the world’s leader, announced that It has received the CE mark, which is an important way in combatting the outbreak of COVID-19 across Europe.
On the basis of product, the market of glycobiology includes kits, enzymes, reagents and instruments. Enzymes has the largest share due to consumable nature of enzymes and its wide uses in many drug discovery procedures and R&D.
Based on application, the global market of glycobiology includes immunology, drug discovery and development, oncology, diagnostics and others. Drug discovery and development is the fastest growing section owing to increase in R&D investment in biotechnology companies and pharmaceutical.
With increasing investment from organizations and government have enabled academic research to develop new glycobiology and glycomics tools. These factors are driving the field of glycoscience and thus driving overall market.
Also, the glycobiology market is emerging mainly due to the rise in expenditure by different pharmaceutical companies on R&D.
Though, the high cost associated with imaging process, lack of skilled technicians and imaging process, technological advancement and stringent government policies hinder the market growth.
About the report:
The global Glycobiology market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire